| Model Number: | MFA-S1G |
| Moq: | 1 |
| Payment Terms: | T/T,L/C |
Single-Channel Dry Fluorescence POCT Analyzer
| Test Items | |||
| Category | Abbreviation | Full Name | Clinical Significance |
| Cardiovascular | cTnI | Cardiac Troponin I | Gold standard for MI diagnosis; preferred myocardial injury marker. |
| CK-MB | Creatine Kinase-MB | Diagnoses acute MI; monitors re-infarction. | |
| Myo | Myoglobin | Early diagnosis of MI; rules out MI. | |
| NT-proBNP | N-terminal Pro-brain Natriuretic Peptide | Detects acute/chronic heart failure; evaluates prognosis. | |
| BNP | Brain Natriuretic Peptide | Detects acute/chronic heart failure; evaluates prognosis. | |
| H-FABP | Heart-type Fatty Acid-binding Protein | Early diagnosis of MI; monitors re-infarction. | |
| D-Dimer | D-Dimer | Rules out pulmonary embolism and deep vein thrombosis. | |
| MPO | Myeloperoxidase | Predicts coronary artery disease and adverse cardiovascular events. | |
| hs-CRP | High-sensitivity C-reactive Protein | Evaluates cardiovascular disease risk; indicates neonatal infection. | |
| Lp-PLA2 | Lipoprotein-associated Phospholipase A2 | Evaluates atherosclerosis and thrombotic disease risk. | |
| ST2 | Soluble Growth Stimulation Expressed Gene 2 | Screens high-risk heart failure; evaluates prognosis. | |
| S100β | S100 Beta | Evaluates brain injury severity and long-term prognosis. | |
| H-FABP/MPO | Heart-type Fatty Acid-binding Protein / Myeloperoxidase | Early warning predictor for acute myocardial infarction. | |
| cTnI/CK-MB/Myo | Cardiac Troponin I / Creatine Kinase-MB / Myoglobin | Diagnoses acute myocardial infarction. | |
| cTnI/NT-proBNP | Cardiac Troponin I / N-terminal Pro-brain Natriuretic Peptide | Early diagnosis and evaluation of chronic heart failure. | |
| cTnI/H-FABP | Cardiac Troponin I / Heart-type Fatty Acid-binding Protein | Predicts adverse cardiovascular events; detects recurrent MI. | |
| Ox-LDL | Oxidized Low-density Lipoprotein | Evaluates coronary heart disease severity and prognosis. | |
| CPP | Copeptin | Rules out acute MI; monitors heart failure and stroke. | |
| Hcy | Homocysteine | Evaluates cardiovascular disease risk; monitors treatment efficacy. | |
| Infection & Inflammation | IL-6 | Interleukin-6 | Early diagnosis of infection; evaluates severity and prognosis. |
| PCT | Procalcitonin | Differentiates infection types; guides antibiotic use. | |
| CRP | C-reactive Protein | Diagnoses inflammation and infection. | |
| SAA | Serum Amyloid A | Differentiates infection types; early diagnosis of infectious diseases. | |
| hs-CRP + CRP | High-sensitivity CRP / C-reactive Protein | Differentiates infection types; monitors antibiotic efficacy. | |
| HBP | Heparin-binding Protein | Diagnoses acute bacterial infection; monitors severity. | |
| SAA/CRP | Serum Amyloid A / C-reactive Protein | Early identifies viral/bacterial infections. | |
| IL-6/PCT | Interleukin-6 / Procalcitonin | Combined diagnosis of sepsis; evaluates prognosis. | |
| HNL | Neutrophil Lipocalin | Differentiates bacterial/viral infections; predicts sepsis. | |
| Maternal & Child Health | LH | Luteinizing Hormone | Evaluates ovarian/testicular function; ovulation detection. |
| Ferritin | Ferritin | Auxiliary diagnosis of iron deficiency anemia/tumors. | |
| PLGF | Placental Growth Factor | Monitors preeclampsia; evaluates liver cancer efficacy. | |
| sFlt-1 | Soluble fms-like Tyrosine Kinase 1 | Monitors preeclampsia; supports clinical decisions. | |
| IGFBP-1 | Insulin-like Growth Factor Binding Protein-1 | Auxiliary diagnosis of premature rupture of membranes. | |
| 25-OH-VD | 25-Hydroxyvitamin D | Auxiliary diagnosis of vitamin D deficiency. | |
| β-HCG | Beta-Human Chorionic Gonadotropin | Auxiliary diagnosis of ectopic/early pregnancy. | |
| AMH | Anti-Müllerian Hormone | Marker of ovarian reserve; reflects antral follicle count. | |
| AFP | Alpha-fetoprotein | Evaluates abnormal pregnancy and Down syndrome risk. | |
| Prog | Progesterone | Auxiliary diagnosis of threatened abortion. | |
| Gastric Function | PGI | Pepsinogen I | Screens atrophic gastritis and gastric cancer risk. |
| PGII | Pepsinogen II | Initial screening indicator for atrophic gastritis/cancer. | |
| PGI/PGII | Pepsinogen I / Pepsinogen II | Monitors H. pylori treatment; screens gastric cancer. | |
| G-17 | Gastrin-17 | Evaluates gastric function with Pepsinogens. | |
| Pepsin | Pepsin | Objective basis for gastroesophageal reflux diagnosis. | |
| Renal Function | NGAL | Neutrophil Gelatinase-associated Lipocalin | Early diagnosis of acute kidney injury; evaluates prognosis. |
| Cys C | Cystatin C | Detects kidney injury; improves diabetic nephropathy diagnosis. | |
| β2-MG | Beta-2 Microglobulin | Reflects renal tubular function; kidney damage marker. | |
| RBP | Retinol-binding Protein | Screens kidney function injury; differentiates liver/kidney syndromes. | |
| mAlb | Microalbumin | Auxiliary diagnosis of kidney diseases. | |
| Thyroid Function | TSH | Thyroid-stimulating Hormone | Diagnoses thyroid abnormalities; checks pituitary function. |
| TT3/TT4 | Total T3 / Total T4 | Routine indicator for hyperthyroidism/hypothyroidism. | |
| TT4 | Total Thyroxine | Screens hyperthyroidism/hypothyroidism; monitors TSH suppression. | |
| TT3 | Total Triiodothyronine | Screens hyperthyroidism/hypothyroidism; monitors TSH suppression. | |
| Tumor Markers | PRL | Prolactin | Evaluates pituitary/prolactinoma and endocrine disorders. |
| CEA | Carcinoembryonic Antigen | Assists malignant tumor diagnosis; differentiates benign/malignant. | |
| Glucose Metabolism | ADPN | Adiponectin | Differentiates pre-diabetes; monitors diabetic complications. |
| HbA1c | Glycated Hemoglobin | Diagnoses diabetes; monitors blood glucose control. | |
| Pulmonary Function | VEGF | Vascular Endothelial Growth Factor | Auxiliary diagnosis of chronic obstructive pulmonary disease. |

FAQ
Q1: What is time-resolved fluorescence immunoassay?
TRFIA uses lanthanide (europium) labeled antibodies with time-gated fluorescence reading. This technology effectively eliminates non-specific background fluorescence, delivering higher sensitivity, better specificity and more stable results than standard fluorescence immunoassays.
Q2: What sample types can be used with this analyzer?
It supports whole blood, serum, plasma and urine samples depending on the specific assay panel. Minimal sample preparation is required, making it well suited for point-of-care and near-patient testing.
Q3: Is this analyzer suitable for small private clinics?
Yes. Its single-channel design, ultra-compact 1.7kg form factor and cost-effective profile make it ideal for primary care clinics, general practitioner offices, small outpatient centers and low-volume satellite testing locations.